Therapeutic monoclonal antibodies at phase 3 clinical study for management of Covid-19

Document Type : Analytic Review

Authors
M. Rezaei 1
S. Handali 2
1 Department of Toxicology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2 Medical Biomaterial Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran
Abstract
The new coronavirus was firstly identified in the late December 2019 that causes severe respiratory and other organ complications in Covid-19 patients. Although many attempts have been employed to introduce and provide effective medications against this infection, there is still no definitive treatment for the infection. However some agents have shown promising effects in patients and some others are in preliminary or clinical studies. Monoclonal antibodies are of great interest in the treatment of Covid-19, but despite the fact that more than 120 clinical trials have been performed or are being completed; only tocilizumab has shown promising results and is sometimes used in therapeutic protocols. In this review, therapeutic monoclonal antibodies against Covid-19 that are currently in phase 3 or higher clinical trial have been discussed.

Keywords

1. AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. International Immunopharmacology. 2020:106455.
2. Tortonese S, Scriabine I, Anjou L, Loens C, Michon A, Benabdelhak M, et al. COVID-19 in patients on maintenance dialysis in the Paris Region. Kidney International Reports. 2020.
3. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B. 2020.
4. Patel S, Saxena B, Mehta P. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. Heliyon. 2021:e06158.
5. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet. 2020;395(10229):1033-4.
6. Diurno F, Numis F, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. European Review for Medical and Pharmacological Sciences. 2020;24(7):4040-7.
7. Widysanto A, Kurniawan A, Lugito NPH, Yuniarti M, Gunawan C, Wiryanto J, et al. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19. Cytokine. 2021;138:155393.
8. Lan S-H, Lai C-C, Huang H-T, Chang S-P, Lu L-C, Hsueh P-R. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. International journal of antimicrobial agents. 2020:106103.
9. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine. 2020.
10. Alzghari SK, Acuna VS. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review. Journal of Clinical Virology. 2020;127:104380.
11. Klopfenstein T, Zayet S, Lohse A, Balblanc J-C, Badie J, Royer P-Y, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Médecine et Maladies Infectieuses. 2020.
12. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. International journal of antimicrobial agents. 2020:105954.
13. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology. 2020.
14. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. The American journal of emergency medicine. 2020.
15. Lescure F-X, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 2021.
16. Gremese E, Cingolani A, Bosello SL, Alivernini S, Tolusso B, Perniola S, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. 2020;27:100553.
17. Temesgen Z, Assi M, Shweta F, Vergidis P, Rizza SA, Bauer PR, et al., editors. GM-CSF neutralization with Lenzilumab in severe COVID-19 pneumonia: A case-cohort study. Mayo Clinic Proceedings; 2020: Elsevier.
18. De Luca G, Cavalli G, Campochiaro C, Della-Torre E, Angelillo P, Tomelleri A, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. The Lancet Rheumatology. 2020;2(8):e465-e73.
19. Generali D, Bosio G, Malberti F, Cuzzoli A, Testa S, Romanini L, et al. Canakinumab as treatment for COVID-19-related pneumonia: a prospective case-control study. International Journal of Infectious Diseases. 2020.
20. Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy AG, et al. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. European journal of internal medicine. 2021.
Pathobiology Reserach
Volume 23, Issue 0
March 2021
Pages 51-56